Member States of the World Health Organization (WHO) have acknowledged that additional time is required to finalize the Pathogen Access and Benefit Sharing (PABS) annex, a crucial component of the proposed WHO Pandemic Agreement. This decision, emerging from the resumed session of the sixth meeting of the Intergovernmental Working Group (IGWG) in Geneva, underscores the intricate challenges in forging a global consensus on equitable pandemic preparedness and response. The PABS system is designed to ensure the rapid sharing of pathogens with pandemic potential and the fair distribution of benefits derived from their use, such as vaccines, diagnostics, and therapeutics. The outcome of these ongoing negotiations is slated for presentation to the Seventy-ninth World Health Assembly (WHA) later this month, where Member States will be asked to consider extending the IGWG’s mandate, potentially until May 2027 or an earlier special session of the WHA in 2026. This extension reflects the profound complexities and diverging national interests inherent in establishing a legally binding framework for global health equity.

The original target for the full adoption and operationalization of the comprehensive Pandemic Agreement, including the PABS annex, has been an ambitious goal since the IGWG’s establishment. The current deferment of the PABS annex finalization inevitably impacts the timeline for the broader agreement’s signature and ratification, pushing back hopes for a fully realized global health security architecture that many public health experts deem essential in a post-COVID-19 world. Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, expressed confidence in overcoming the differences, stating, "Real progress was made on the PABS annex and I am confident through continued negotiations differences will be overcome." He emphasized the urgent imperative, reminding Member States that "the next pandemic is a matter of when, not if," and characterizing the PABS annex as "the last piece of the puzzle not only for the Pandemic Agreement but all initiatives that WHO and Member States have implemented as a result of lessons learned from the COVID-19 pandemic." This highlights the annex’s foundational role in achieving the overarching goals of the pandemic accord.

The Genesis of a Global Accord: Lessons from COVID-19

The impetus for the WHO Pandemic Agreement emerged from the stark and often tragic lessons learned during the COVID-19 pandemic. The global health crisis, which officially accounted for nearly 7 million deaths but whose true toll is estimated to be significantly higher, exposed profound inequities in access to essential medical countermeasures, diagnostics, and vaccines. While some high-income countries swiftly secured vast quantities of vaccines, many low- and middle-income nations struggled to access even basic supplies, leading to a phenomenon dubbed "vaccine apartheid" by critics. This uneven distribution not only exacerbated health disparities but also prolonged the pandemic’s economic and social disruption worldwide, with global GDP shrinking by 3.4% in 2020 and unprecedented surges in poverty and food insecurity. The pandemic underscored the interconnectedness of global health and the undeniable truth that no country is safe until all countries are safe.

In response, global leaders and public health advocates called for a robust, legally binding international instrument to prevent, prepare for, and respond to future pandemics more effectively and equitably. The process formally began in December 2021 when the World Health Assembly, the WHO’s decision-making body, established an Intergovernmental Negotiating Body (INB) to draft and negotiate a new international agreement on pandemic preparedness and response. This initiative aimed to complement and strengthen the existing International Health Regulations (IHR) (2005), which, despite their importance, proved insufficient to address the scale and speed of the COVID-19 crisis, particularly concerning global cooperation and equitable resource allocation. The INB’s mandate was broad, encompassing areas from surveillance and early warning systems to research and development, supply chains, and, critically, pathogen access and benefit sharing. The subsequent establishment of the Intergovernmental Working Group (IGWG) was a direct outcome of this initial mandate, focusing specifically on the intricacies of the PABS system as a core pillar of the nascent agreement.

The Critical Role of Pathogen Access and Benefit Sharing (PABS)

At its heart, the PABS system is designed to rectify historical injustices and structural imbalances in global health. Its dual objective is unequivocal: to ensure the rapid and systematic sharing of pathogens with pandemic potential, and concomitantly, the fair and equitable sharing of the benefits derived from their use. This includes, but is not limited to, vaccines, therapeutics, diagnostics, and related technologies. Historically, pathogen sharing has often occurred on an ad hoc basis, sometimes leading to situations where countries that rapidly shared critical samples found themselves at the back of the queue for resultant medical products. A notable example is the H5N1 avian influenza outbreaks in the mid-2000s, where Indonesia temporarily withheld virus samples due to concerns that pharmaceutical companies would use them to develop vaccines that would then be unaffordable or inaccessible to its own population. This incident highlighted the deep mistrust and the urgent need for a structured, legally sound framework.

The PABS annex aims to operationalize the principle of solidarity by establishing clear mechanisms. For instance, it envisions a global system where countries swiftly deposit pathogen samples into a WHO-coordinated network of laboratories. In return, there would be predefined commitments for manufacturers and researchers to provide a certain percentage of vaccines, treatments, or diagnostic tools at affordable prices, or to contribute to a global fund for pandemic preparedness, or to facilitate technology transfer and capacity building in developing countries. This "quid pro quo" mechanism is intended to create a virtuous cycle of cooperation, ensuring that all nations benefit from the collective effort to combat pandemics, rather than perpetuating a system where wealthier nations disproportionately reap the rewards of global scientific collaboration. Finalizing the PABS Annex is not merely a technicality; it is, as the original text notes, "necessary so countries can proceed with signature and ratification of the Pandemic Agreement," underscoring its pivotal role as a prerequisite for the entire accord’s legitimacy and effectiveness. Without a robust PABS framework, the broader agreement risks becoming an aspirational document devoid of the practical mechanisms needed to ensure equity.

Navigating the Negotiation Labyrinth: Hurdles and Progress

The current delay in finalizing the PABS annex underscores the immense technical and legal complexities involved in achieving consensus among 194 diverse Member States. As Ambassador Tovar da Silva Nunes of Brazil, IGWG Bureau Co-Chair, aptly put it, "Finalizing a document of such technical and legal complexity requires precision and dedication, both of which the Member States have demonstrated in full. We are not there yet, but with an extension of our negotiations, we will get there." The negotiations grapple with a myriad of contentious issues, primarily revolving around intellectual property rights, technology transfer, and financing mechanisms.

One of the most significant sticking points is the tension between public health imperatives and the commercial interests of pharmaceutical companies. High-income countries, often home to major pharmaceutical innovators, advocate for strong intellectual property protections, arguing that these incentives drive research and development. Conversely, many low- and middle-income countries, supported by global health advocates, contend that during a pandemic, intellectual property rights should not impede rapid and equitable access to life-saving products. They call for provisions that facilitate compulsory licensing, technology transfer, and the waiver of certain IP rights, similar to the discussions around the TRIPS waiver at the World Trade Organization during COVID-19. Finding a balance that respects innovation while ensuring global equity is a delicate act.

Furthermore, defining the scope and nature of "benefit sharing" itself presents challenges. What constitutes a fair share? Is it a percentage of production, a contribution to a fund, or direct technology transfer? How will these benefits be distributed, and who will oversee the process? The legal architecture must be robust enough to withstand potential challenges and flexible enough to adapt to future pandemic scenarios. The issue of financing is also critical; establishing a sustainable funding mechanism for preparedness, response, and benefit sharing requires significant political will and financial commitments from all Member States, not just those with high GDPs. These are not merely technical details but fundamental questions of global governance, economic justice, and shared responsibility.

Voices from the Frontline: Calls for Urgency and Equity

The statements from WHO leadership and the IGWG co-chairs reflect a shared understanding of both the progress made and the critical work that remains. Dr. Tedros’s emphasis on the "sense of urgency" resonates deeply with the global health community, which has long advocated for proactive measures rather than reactive responses. Public health experts and civil society organizations have consistently highlighted that delays in establishing such a framework could have catastrophic consequences in the face of another global health emergency. They point to the fact that preparedness investments, while seemingly costly in peacetime, are dwarfed by the economic and human toll of an uncontrolled pandemic. Estimates suggest that the global economy lost trillions of dollars due to COVID-19, making proactive investment in a system like PABS a fiscally responsible decision.

Mr. Matthew Harpur, IGWG Co-Chair, reiterated the commitment of Member States, stating, "WHO Member States have demonstrated strong and continuing commitment to negotiations on a Pathogen Access and Benefit Sharing system annex. The IGWG Bureau is confident we are moving in the right direction to finalize the PABS annex, and in doing so provide the WHO Pandemic Agreement with the framework needed to ensure countries are better, and more equitably, prepared and protected for the next pandemic." This collective determination, despite the protracted negotiations, offers a glimmer of hope that a workable solution will ultimately be found. However, observers from organizations like Médecins Sans Frontières and Oxfam frequently remind negotiators that "equity cannot be an afterthought" and that any agreement must genuinely prioritize the needs of vulnerable populations.

A Timeline of Endeavors: Past Milestones and Future Prospects

The journey towards a comprehensive global pandemic agreement has been lengthy and iterative, reflecting the complexities of multilateral diplomacy in health.

• December 2021: The World Health Assembly established the Intergovernmental Negotiating Body (INB) to draft and negotiate a new international agreement on pandemic preparedness and response.
• Early 2022 – Present: Multiple rounds of INB and IGWG meetings have been held in Geneva, engaging experts and diplomats from all 194 WHO Member States. These sessions involved intense textual negotiations, informal consultations, and political dialogues aimed at bridging divides.
• May 2025 (Original Target/Mandate Adoption): The foundational work towards a comprehensive WHO Pandemic Agreement, aimed at bolstering global health security, began in the aftermath of the COVID-19 pandemic, leading to the establishment of the Intergovernmental Working Group (IGWG) with a mandate to draft and negotiate its critical components, including the Pathogen Access and Benefit Sharing (PABS) system. While significant progress has been made on the broader framework, the PABS annex remains a pivotal element requiring further deliberation before the full agreement can proceed to signature and ratification. This date, previously seen as a potential milestone for the full agreement, now highlights the shifting timelines due to PABS complexities.
• Later this month (May 2024): The outcome of the recent IGWG session, including the need for extended negotiations on PABS, will be presented to the Seventy-ninth World Health Assembly.
• July 6-17, 2026: The IGWG is scheduled to hold its seventh meeting, indicating a clear path forward for continued deliberations.
• May 2027 (Proposed New Deadline): The WHA will be asked to consider extending the IGWG’s work to submit the final outcome to the next Assembly, or potentially earlier via a special session of the WHA in 2026.

This chronology illustrates the sustained commitment to the agreement, even as the PABS annex proves to be the most formidable hurdle. The extension of the timeline, while potentially frustrating for those advocating for faster action, also provides a crucial window for Member States to iron out the remaining differences and build a truly robust and universally acceptable framework.

The Broader Landscape of Global Health Governance

The WHO Pandemic Agreement and its PABS annex are not isolated initiatives but integral components of a broader effort to reform and strengthen global health governance. They run in parallel with ongoing amendments to the International Health Regulations (IHR), which primarily focus on disease surveillance, reporting, and response capacities. While the IHR provide a legal framework for responding to acute public health events, the Pandemic Agreement aims to address systemic gaps related to equity, financing, and sustained international cooperation, especially regarding the equitable distribution of resources during a crisis.

The discussions around PABS also intersect with long-standing debates on health as a human right and the principle of "common but differentiated responsibilities" in international law. Developing countries, often bearing the brunt of infectious diseases with fewer resources, argue that wealthier nations have a greater responsibility to contribute to global health security, given their historical advantages and capacities. This principle recognizes that while all states share a common responsibility to protect global health, their differing capabilities and contributions require a differentiated approach to obligations and burden-sharing. The PABS annex seeks to codify this principle into practical mechanisms, transforming aspirational statements into actionable commitments. The success of PABS will thus be a litmus test for the international community’s genuine commitment to multilateralism and health equity.

Economic and Social Imperatives for a Unified Approach

The economic case for a robust PABS system and a comprehensive Pandemic Agreement is compelling. The World Bank estimates that pandemics could cost the global economy an average of $3.7 trillion per year, or 5% of global GDP. The COVID-19 pandemic alone resulted in unprecedented economic contractions and massive fiscal expenditures globally. A study by the WHO and the World Bank indicated that investing approximately $10.5 billion annually in pandemic preparedness could prevent future losses of hundreds of billions, if not trillions, of dollars. The PABS system, by ensuring rapid pathogen sharing and equitable access to countermeasures, directly contributes to mitigating these economic risks. It fosters global trust and collaboration, which are essential for swift and coordinated responses that can minimize economic disruption.

Beyond economics, the social imperative is equally profound. Pandemics disproportionately affect vulnerable populations, exacerbating existing inequalities. Access to vaccines, diagnostics, and therapeutics is not just an economic issue but a matter of social justice and human dignity. A functional PABS system would ensure that health is not a privilege but a right, accessible to all, regardless of nationality or economic status. This includes fostering local manufacturing capabilities and technology transfer to empower countries to produce their own essential medical products, thereby building resilience and reducing reliance on external supply chains that can falter during crises. The long-term societal benefits of such an equitable system — from reduced mortality and morbidity to enhanced social stability and trust in public health institutions — are immeasurable.

Looking Ahead: The Path to a Resilient Future

The extension of negotiations for the PABS annex signifies a challenging but necessary phase in the development of the WHO Pandemic Agreement. While a faster resolution would be ideal, the meticulous approach highlights the gravity of the issues at stake and the collective desire to forge an agreement that is not only effective but also universally accepted and implementable. The commitment from Member States, as echoed by the IGWG co-chairs, suggests that despite the difficulties, there is a strong will to "get there."

The implications of this delay are multifaceted. On one hand, it underscores the persistent geopolitical and economic divides that complicate global health cooperation. On the other, it provides an opportunity for more thorough deliberation, potentially leading to a stronger, more resilient, and truly equitable framework. The success of the PABS annex and the broader Pandemic Agreement will hinge on the ability of Member States to transcend national self-interest and embrace a shared vision of global solidarity. As the world awaits the next pandemic, the ability to rapidly share pathogens and equitably distribute the tools to fight them remains the cornerstone of collective global health security. The upcoming World Health Assembly will be a critical juncture, determining the mandate and resources for the IGWG to complete this vital "last piece of the puzzle," laying the groundwork for a more prepared and just world in the face of future health crises. The stakes could not be higher for global health, equity, and the very fabric of international cooperation.